title: Does more intensive therapy have effects on mantle cell lymphoma? A clinical experience from the Lymphoma Treatment Study Group in Japan.
authors.affiliation: Department of Hematology and Rheumatology, Division of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi-ku, Tokyo, Japan. javis@med.nihon-u.ac.jp.|Lymphoma Treatment Study Group, Nara, Japan. javis@med.nihon-u.ac.jp.
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Miura
authors.affiliation: Lymphoma Treatment Study Group, Nara, Japan.
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Takasaki
authors.affiliation: Lymphoma Treatment Study Group, Nara, Japan.
authors.forename: Hideki
authors.initials: H
authors.lastname: Tsujimura
authors.affiliation: Lymphoma Treatment Study Group, Nara, Japan.
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kanno
authors.affiliation: Lymphoma Treatment Study Group, Nara, Japan.
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Maeda
authors.affiliation: Lymphoma Treatment Study Group, Nara, Japan.
authors.forename: Naoto
authors.initials: N
authors.lastname: Tomita
authors.affiliation: Lymphoma Treatment Study Group, Nara, Japan.
authors.forename: Kazue
authors.initials: K
authors.lastname: Takai
authors.affiliation: Lymphoma Treatment Study Group, Nara, Japan.
authors.forename: Yasufumi
authors.initials: Y
authors.lastname: Masaki
authors.affiliation: Lymphoma Treatment Study Group, Nara, Japan.
authors.forename: Jun
authors.initials: J
authors.lastname: Takizawa
authors.affiliation: Lymphoma Treatment Study Group, Nara, Japan.
authors.forename: Hiraku
authors.initials: H
authors.lastname: Mori
authors.affiliation: Lymphoma Treatment Study Group, Nara, Japan.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Terasaki
authors.affiliation: Lymphoma Treatment Study Group, Nara, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Yoshida
authors.affiliation: Department of Hematology and Rheumatology, Division of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi-ku, Tokyo, Japan.|Lymphoma Treatment Study Group, Nara, Japan.
authors.forename: Jin
authors.initials: J
authors.lastname: Takeuchi
authors.affiliation: Lymphoma Treatment Study Group, Nara, Japan.
authors.forename: Shigeki
authors.initials: S
authors.lastname: Motomura
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002869:Chromosome Aberrations; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy / Q000379:methods*; D019938:Cyclin D1 / Q000096:biosynthesis*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007564:Japan; D007621:Karyotyping; D020522:Lymphoma, Mantle-Cell / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D012189:Retrospective Studies; D012307:Risk Factors; D000069283:Rituximab; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D014182:Transplantation, Autologous; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D019938:Cyclin D1; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone